TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 recep...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Palmblad, Jan, Björkholm, Magnus, Kutti, Jack, Lärfars, Gerd, Löfvenberg, Eva, Markevärn, Berit, Merup, Mats, Mauritzson, Nils, Westin, Jan, Samuelsson, Jan, Birgegård, Gunnar
Formato: Artigo
Idioma:Inglês
Publicado: Ivyspring International Publisher 2008
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2293642/
https://ncbi.nlm.nih.gov/pubmed/18414650
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares